International Stem Cell Corporation reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 0.331 million compared to USD 0.899 million a year ago. Basic loss per share from continuing operations was USD 0.04 compared to USD 0.11 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1134 USD | +117.66% | +117.66% | +82.90% |
1st Jan change | Capi. | |
---|---|---|
+82.90% | 908K | |
+17.09% | 45.34B | |
+42.10% | 40.42B | |
-9.70% | 37.92B | |
+33.28% | 31.75B | |
-8.98% | 27.71B | |
+13.37% | 26.52B | |
+44.11% | 13.96B | |
+32.33% | 12.44B | |
-7.26% | 11.26B |
- Stock Market
- Equities
- ISCO Stock
- News International Stem Cell Corporation
- International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2022